Analyst Targets UBS — Buy, $149 JP Morgan — Overweight, $145 Stifel — Buy, $145 Bernstein — Buy, $142 Bank…
Gold Is at $3,693 and the Miners Are Telling You Where It Goes Next
With the dollar at a 19-month high and the 10-year near 5.10%, the roadmap points at $3,500.
Lilly’s $5.9B Stipple Bio Deal Looks Bigger Than It Is
Two oncology deals show how Lilly is deploying GLP-1 cash, and why the headline number is not cash spent today.
Tesla Sold 8,817 Cars in China Last Month. Its Valuation Needs Millions.
An October low in China retail sales sharpens the question every long-term Tesla shareholder has to answer: how much faith…
Dr. Ron Paul: “This is even worse than the big Socialist victory”
A note from our friends at MarketWise(ad) Dear Reader, The Democratic Socialists won big at the polls this election cycle.…
Strategy and Coinbase Are Breaking Down. The Equity Trade.
With bitcoin near $64,600 and Strategy on a roughly $9B paper loss, the pressure is in the stocks, and Nov.…
Alibaba Says It Cut AI Task Costs 62%. Who Keeps It?
Qwen4-Max brings sharp pricing and bold benchmark claims, but the closed-weights choice hints at where AI profits may land.
Nvidia’s China Revenue Is Now Washington’s Business
Analyst Targets CLSA: Downgraded to Outperform (from High-Conviction Outperform), target cut to $255 from $425, maintains earnings estimates, compressed multiple…
This $5 Stock Could Hit $50 by January This “Musk Target” to 10X By January 1st?
A note from our friends at The Oxford Club(ad) Dear reader, This stock trades for under $5 today. Dr. Mark…
Roche Gets an FDA Approval for a Rare Kidney Disease
Gazyva in primary membranous nephropathy adds growth to Roche
